Status:
RECRUITING
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
Lead Sponsor:
Parc de Salut Mar
Collaborating Sponsors:
Universitat Oberta de Catalunya
Conditions:
Fibromyalgia
Psychological Trauma
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
Fibromyalgia (FM) is a generalized, widespread chronic pain disorder and has an estimated prevalence of 2%-4% in the general population. Current pharmacological and psychological interventions frequen...
Detailed Description
Fibromyalgia (FM) affects 2-4% of the general population with typical symptoms such as generalized and widespread pain, sleep disturbances, problems in memory and attention, anxiety and depression. Ph...
Eligibility Criteria
Inclusion
- Age between 18 and 70 years old
- Mean pain score of at least 4 on the visual analog scale (VAS) in the two weeks preceding the clinical trial
- Presence of one or more traumatic events causing current trauma-related symptoms
- Current clinical symptoms of depression and/or anxiety
- 2 weeks of stable medication
Exclusion
- Comorbid autoimmune or chronic inflammatory disease
- Neurological or serious medical diseases
- Bipolar disorder, schizoaffective disorder and schizophrenia
- Suicidal ideation
- Previous EMDR therapy in the past two years
- Substance abuse/dependency within 1 month prior to participation (except for nicotine abuse/dependency),
- Pending FM-related litigation or disability
- Metallic implants in the head
- Positive test for pregnancy
- Skin sensitivity diseases (psoriasis, eczema, dermatitis, etc.)
Key Trial Info
Start Date :
January 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04084795
Start Date
January 21 2025
End Date
December 31 2026
Last Update
August 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Forum (Parc de Salut Mar)
Barcelona, Catalonia, Spain, 08019